High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

Cell Cycle

Volumn 8, Issue 8, 2009, Pages 1176-1184

  Czarna, Anna ^a   Popowicz, Grzegorz M ^a   Pecak, Aleksandra ^b   Wolf, Siglinde ^a   Dubin, Grzegorz ^b   Holak, Tad A ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cancer; FP assay; Mdm2; Mdm4; Mdmx; p53; Structure

Indexed keywords

MUTANT PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; FLUORESCENCE POLARIZATION; HUMAN; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; STRUCTURAL PROTEOMICS;

EID: 65949087007     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.8.8185     Document Type: Article

References (44)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-283
3. Toledo F, Wahl M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Canc 2006; 6:909-923
4. Marine JCW, Dyer MA, Jochemsen AG. MDMX: From bench to bedside. J Cell Sci 2007; 120:371-378 (Pubitemid 46332500)
5. Marine JC and Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle 2004; 900-904
6. Haupt Y. p53 Regulation: a family affair. Cell Cycle 2004; 3:884-885 (Pubitemid 40179466)
7. Stommel JM and Wahl GM. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 2005; 4:411-417 (Pubitemid 41359726)
8. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Ann Rev Bioch 2008; 77:557-582
9. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Disc 2008; 7:979-987
10. Marx J. Oncology, Recruiting the cell's own guardian for cancer therapy. Science 2007; 315:1211-1213 (Pubitemid 46364233)
11. Bixby D, Lisa Kujawski L, Shaomeng Wang S, Sami N. Malek SN. The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle 2008; 7:971-979
12. Hu CQ, Hu YZ. Small molecule inhibitors of the p53-MDM2. Curr Med Chem 2008; 15:1720-1730
13. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13:23-31. (Pubitemid 46027725)
14. Cheok CF, Lane DP. New developments in small molecules targeting p53 pathways in anticancer therapy. Drug Dev Res 2008; 69:289-296
15. Shangary S, Wang SM. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318-5324
16. Murray JK, Gellman SH. Targeting protein-protein interactions: Lessons from p53/MDM2. Biopolymers 2007; 88:657-686
17. Dömling A. Small molecular weight protein-protein interaction antagonists - an insurmountable challenge? Curr Opin Chem Biol 2008; 12:281-291
18. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Disc Dev 2008; 11:666-674
19. Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, et al. Cell Cycle 2007; 6:2386-2392
20. Meulmeester E, Jochemsen AG. p53: A guide to apoptosis. Curr Cancer Drug Targ 2008; 8:87-97.
21. Lehman JA, Eitel JA, Batuello CN, et al. Therapeutic considerations for Mdm2: not just a one trick pony. Expert Opin Drug Dicov 2008; 3:1309-1321
22. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009; 7:1-11.
23. Xia MX, Knezevic D, Tovar C, Huang BY, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7:1604-1612
24. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of HDM2. Science 2004; 303:844-848
25. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Proc Natl Acad Sci USA 2008; 105:3933-3938
26. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-66
27. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008; 7:2441-2443
28. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281:33030-33035 (Pubitemid 46036685)
29. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006; 281:33036-33044 (Pubitemid 46036686)
30. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66:3169-3176
31. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, Tavares G, et al. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide-Analogues reveal Surprising Conformational Changes. J Biol Chem 2009; In press 10.1074/jbc.M809096200.
32. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2006; 67:8810-8817
33. Zondlo SC, Lee AE, Zondlo NJ. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. Biochemistry 2006; 45:11945-11957 (Pubitemid 44500619)
34. Dastidar SG, Lane DP, Verma CV. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 2008; 130:13514-13515
35. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-953
36. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48:909-912
37. Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997; 269:744-56.
38. Xinyj Huang. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 2003; 8:34-38
39. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4:67-73. (Pubitemid 29278954)
40. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001; 40:336-344
41. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 1993; 26:795-800.
42. Collaborative Computational Project, Number 4 Acta Crystallogr D Biol Crystallogr 1994; 50:760-763
43. McRee DE. XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density. J Struc Biol 1999; 125:156-165
44. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240-255 (Pubitemid 27235885)